The recombinant MAGE-A3 protein was therapeutically administered in nearly 3,000 patients following the resection of lung cancer tumor in the largest therapeutic study for lung cancer, MAGRIT (MAGE-A3 as Adjuvant NSCLC Immunotherapy) [19]. The gene discussed is MAGEA3; the disease is non-small cell lung carcinoma.